GMAB vs. LLY: Genmab vs. Eli Lilly Stock Comparison

Company Profile

Genmab (GMAB) and Eli Lilly (LLY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GMAB is classified in Biotechnology while LLY is classified in Pharmaceuticals.

Eli Lilly (LLY) trades as ordinary local shares, while Genmab (GMAB) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Genmab (GMAB) at 12.07% and Eli Lilly (LLY) at 86.02% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Eli Lilly (LLY) at 31.90% keeps the most of each sales dollar — above its industry’s net margin range — and Genmab (GMAB) at 16.97% also retains a top-quartile share.

Both Genmab (GMAB) at 37.15% and Eli Lilly (LLY) at 53.66% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Genmab (GMAB) at 19.19% and Eli Lilly (LLY) at 44.70% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Eli Lilly (LLY) at 95.99% sits in the top EPS growth quartile, while Genmab (GMAB) at -9.23% is closer to the peer norm — faster per-share earnings growth for LLY.

Growth Metrics

Financial Strength

Both Genmab (GMAB) at 2.45 and Eli Lilly (LLY) at 1.39 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Genmab (GMAB) at 0.82 and Eli Lilly (LLY) at 1.23 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Genmab (GMAB) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a yield of 0.49%, ranking against industry peers normally.

Genmab (GMAB) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Eli Lilly (LLY) reports a payout of 21.71%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both Genmab (GMAB) at 45.84 and Eli Lilly (LLY) at 43.95 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.

On P/S ratio, both Genmab (GMAB) at 7.68 and Eli Lilly (LLY) at 13.95 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Genmab (GMAB) at 5.36 sits near its industry’s typical P/B ratio, while Eli Lilly (LLY) at 29.96 prices above its benchmark range — LLY looks rich relative to book.

Valuation Metrics